Co-Diagnostics Inc CODX

$1.15 +0.05 (4.55%)

Valuation

Market cap
7,679,000
Revenue TTM
$620,000
Net income TTM
$-46,900,000
PE ratio
0.00
Forward PE
—
Profit margin
-7,564.52%
Debt to equity
0.00

Trading

Volume
886,600
Avg volume
378,664
Day's range
$1.05 – $1.17
Shares out
6,981,000
Stochastic %K
65%
Beta
2.90
Analysts
Sell
Price target
$4.00

Price

Company profile

Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provides PCR diagnostic test...

Show more

Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, malaria, dengue, human papillomavirus, chikungunya, and Zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. Co-Diagnostics, Inc. was incorporated in 2013 and is based in Salt Lake City, Utah.

Industry
Medical Devices
Sector
Healthcare
Phone
801 438 1036
Website
https://co-dx.com
Address
2401 S. Foothill Drive, Suite D, Salt Lake City, United States

Latest news